Myocardial protection against Ischemia-Reperfusion Injury by GLP-1: Molecular mechanisms

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 6, 2012, Pages 387-390

  Birnbaum, Yochai ^a,b,c   Ye, Yumei ^a   Bajaj, Mandeep ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; LIPOXIN A; LIRAGLUTIDE; MK 0626; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE III INHIBITOR; PROTEIN KINASE B; SITAGLIPTIN; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; GLUCOSE BLOOD LEVEL; HEART PROTECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; GLUCAGON-LIKE PEPTIDE 1; HEART; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION;

EID: 84869804106     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0095     Document Type: Note

References (45)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439. (Pubitemid 350041474)
2. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151. (Pubitemid 40105106)
3. Bose AK, Mocanu MM, Carr RD, et al. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19:9-11. (Pubitemid 40767767)
4. Bose AK, Mocanu MM, Carr RD, et al. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6k pathway. Cardiovasc Drugs Ther 2007; 21:253-256. (Pubitemid 47387464)
5. Ossum A, van Deurs U, Engstrom T, et al. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 2009;60:411-417.
6. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146: 243-249.
7. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation 2008;117: 2340-2350. (Pubitemid 351653542)
8. Matsubara M, Kanemoto S, Leshnower BG, et al. Single dose GLP-1-tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 2011;165:38-45.
9. Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008;19:77-83. (Pubitemid 351846438)
10. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983.
11. Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagonlike peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011;43:300-305.
12. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1(9-36)amide- mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531.
13. Brown SB, Libonati JR, Selak MA, et al. Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther 2010;24:197-205.
14. Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6:e23570.
15. Kavianipour M, Ehlers MR, Malmberg K, et al. Glucagonlike peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003;24:569-578. (Pubitemid 36829346)
16. Kristensen J, Mortensen UM, Schmidt M, et al. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009;9:31.
17. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
18. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-1499.
19. Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct sizelimiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298:H1454-H1465.
20. Ku HC, Chen WP, Su MJ. Dpp4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011;384:197-207.
21. Huisamen B, Genis A, Marais E, et al. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, prediabetic rats. Cardiovasc Drugs Ther 2011;25:13-20.
22. Ye Y, Perez-Polo JR, Aguilar D, et al. The potential effects of anti-diabetic medications on myocardial ischemiareperfusion injury. Basic Res Cardiol 2011;106:925-952.
23. Birnbaum Y, Castillo AC, Ling S, et al. Amplification of the myocardial infarct size limiting effects of exenatide with cilostazol, a phosphodiesterase III inhibitor [abstract]. J Am Col Cardiol 2012;59:A110.
24. Birnbaum Y, Castillo AC, Qian J, et al. Phosphodiesterase III inhibition increases camp levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drug Ther 2012 Aug 31. [Epub ahead of print].
25. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: From bench to bedside. Cardiovasc Res 2012;94:316-323.
26. Sanada S, Asanuma H, Tsukamoto O, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004;110:51-57. (Pubitemid 38880133)
27. Inserte J, Garcia-Dorado D, Ruiz-Meana M, et al. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc Res 2004;64:105-114. (Pubitemid 39208927)
28. Sanada S, Kitakaze M, Papst PJ, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: The role of protein kinase A and p38 mitogenactivated protein kinase. Circulation 2001;104:705-710. (Pubitemid 32738527)
29. Vadas O, Burke JE, Zhang X, et al. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 2011;4.
30. Cosentino C, Di Domenico M, Porcellini A, et al. P85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene 2007;26: 2095-2103. (Pubitemid 46514751)
31. De Gregorio G, Coppa A, Cosentino C, et al. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene 2007;26:2039-2047. (Pubitemid 46514747)
32. Bellis A, Castaldo D, Trimarco V, et al. Cross-talk between PKA and AKT protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler Thromb Vasc Biol 2009;29:1207-1212.
33. Manickavasagam S, Ye Y, Lin Y, et al. The cardioprotective effect of a statin and cilostazol combination: Relationship to AKT and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 2007;21:321-330. (Pubitemid 47598922)
34. Harris MB, Blackstone MA, Sood SG, et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004;287:H560-H566. (Pubitemid 38955284)
35. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70:240-253.
36. Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999;68:821-861. (Pubitemid 29449210)
37. Marais E, Genade S, Lochner A. CREB activation and ischaemic preconditioning. Cardiovasc Drugs Ther 2008;22:3-17.
38. Nagy N, Shiroto K, Malik G, et al. Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol 2007;42:981-990. (Pubitemid 46678032)
39. Das S, Cordis GA, Maulik N, et al. Pharmacological preconditioning with resveratrol: Role of CREB-dependent bcl-2 signaling via adenosine a3 receptor activation. Am J Physiol Heart Circ Physiol 2005;288:H328-H335. (Pubitemid 40023863)
40. Eliseev RA, Vanwinkle B, Rosier RN, et al. Diazoxidemediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB. J Biol Chem 2004;279:46748-46754. (Pubitemid 39518323)
41. Mocanu MM, Field DC, Yellon DM. A potential role for PTEN in the diabetic heart. Cardiovasc Drugs Ther 2006;20: 319-321. (Pubitemid 44701164)
42. Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: The importance of AKT phosphorylation. Diabetes 2005;54:2360-2364. (Pubitemid 41134263)
43. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, Huang MH, Uretsky BF, Perez-Polo Jr. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006;114:929-935. (Pubitemid 44337136)
44. Ye Y, Lin Y, Perez-Polo JR, et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase a determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008;181:3515-3523.
45. Keyes KT, Ye Y, Lin Y, et al. Resolvin e1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol 2010;299:H153-H164.